Novartis (NYSE:NVS) recently got results from a mid-stage trial for a new drug and, so far, things look pretty good. There is indirect evidence that the company’s experimental drug could help up to half of heart failure patients who currently have no effective treatment, Reuters reports.
The drug is known as LCZ696 and appears to reduce the protein NT-proBNP, which is linked to heart failure in other studies.
This is good news for Novartis, as the company’s top-selling blood pressure pill is currently facing great amounts of generic competition. The drug saw sales of around $5.7 billion last year.
Still, things are in the early stages and the company has not officially decided whether it will advance the drug to final-stage testing for the most recent group of patients. And many experts were wary about reading too much into the trial’s results.
The company also has a few other drugs that are currently undergoing testing.
More New Drugs on the Horizon
- Eli Lily’s Alzheimer’s drug
- Arena’s weight loss drug 
- Novartis’ breast cancer drug
- Two different diet drugs